Business Description
Novartis AG
ISIN : CH0038459415
Total Employee Number:
75,267Compare
Compare
Traded in other countries / regions
NOVN.SwitzerlandNVS.USA0QLR.UKNOT.Germany1NOVN.ItalyNVS.CanadaNOVNN.MexicoNVS.ArgentinaN1VS34.Brazil IPO Date
2014-10-15Description
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 1.22 | |||||
Debt-to-EBITDA | 2.07 | |||||
Interest Coverage | 14.16 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.63 | |||||
Beneish M-Score | -2.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.8 | |||||
3-Year EBITDA Growth Rate | 14.3 | |||||
3-Year EPS without NRI Growth Rate | 30.1 | |||||
3-Year FCF Growth Rate | 6.9 | |||||
3-Year Book Growth Rate | -9.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 6.24 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.41 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.85 | |||||
Quick Ratio | 0.65 | |||||
Cash Ratio | 0.22 | |||||
Days Inventory | 166.33 | |||||
Days Sales Outstanding | 58.98 | |||||
Days Payable | 118.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 0.4 | |||||
3-Year Average Share Buyback Ratio | 3.4 | |||||
Shareholder Yield % | 4.9 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 75.39 | |||||
Operating Margin % | 30.44 | |||||
Net Margin % | 23.94 | |||||
EBITDA Margin % | 39.6 | |||||
ROE % | 31.74 | |||||
ROA % | 12.28 | |||||
ROIC % | 13.88 | |||||
3-Year ROIIC % | -44.39 | |||||
ROC (Joel Greenblatt) % | 140.21 | |||||
ROCE % | 21.58 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 22.28 | |||||
Forward PE Ratio | 20.99 | |||||
PE Ratio without NRI | 22.28 | |||||
Shiller PE Ratio | 23.78 | |||||
Price-to-Owner-Earnings | 17.03 | |||||
PEG Ratio | 8.91 | |||||
PS Ratio | 5.33 | |||||
PB Ratio | 7.82 | |||||
Price-to-Free-Cash-Flow | 18.89 | |||||
Price-to-Operating-Cash-Flow | 15.73 | |||||
EV-to-EBIT | 19.87 | |||||
EV-to-EBITDA | 15.08 | |||||
EV-to-Revenue | 5.97 | |||||
EV-to-FCF | 21.1 | |||||
Price-to-Projected-FCF | 1.76 | |||||
Price-to-Median-PS-Value | 1.32 | |||||
Earnings Yield (Greenblatt) % | 5.03 | |||||
FCF Yield % | 5.39 | |||||
Forward Rate of Return (Yacktman) % | 5.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Novartis AG Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | |||
| EPS (TTM) (CHF) | 2.8 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (CHF) | - | ||
| 20-Day SMA (CHF) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (CHF) | 0 - 0 | ||
| Shares Outstanding (Mil) | 2,119.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novartis AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novartis AG Stock Events
| Event | Date | Price (CHF) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-27 | In 107 days | ||
| Third quarter earnings results for 2026 | 2026-10-27 | In 107 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-21 | In 9 days | ||
| Second quarter earnings results for 2026 | 2026-07-21 | In 9 days | ||
| First quarter earnings conference call for 2026 | 2026-04-28 14:00 | -- | ||
| First quarter earnings results for 2026 | 2026-04-28 | -- | ||
| General meeting for 2026 | 2026-03-06 10:00 | -- | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-04 14:00 | -- | ||
| Annual report for 2025 | 2026-02-04 | -- | ||
| Fourth quarter earnings results for 2025 | 2026-02-04 | -- |
Show
Entries
Novartis AG Frequently Asked Questions
What is Novartis AG(LTS:0QM7)'s stock price today?
The current price of LTS:0QM7 is CHF0.00. The 52 week high of LTS:0QM7 is CHF0.00 and 52 week low is CHF0.00.
When is next earnings date of Novartis AG(LTS:0QM7)?
The next earnings date of Novartis AG(LTS:0QM7) is 2026-07-21.
Does Novartis AG(LTS:0QM7) pay dividends? If so, how much?
Novartis AG(LTS:0QM7) does not pay dividend.
Press Release
Articles on Novartis AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers